Paris – How effective are COVID-19 vaccines if your immune system is compromised by HIV, cancer or a recent organ transplant?
Faced with very little data — and fears that some of these patients could be particularly vulnerable to the virus — scientists are working to identify how best to protect them.
In one of the largest research projects into the issue so far, dozens of French hospitals have launched a two-year study of some 10,000 people to help shed light on how people with these conditions respond to immunization against the novel coronavirus.
“The goal is to find out how we can best protect those patients,” said Odile Launay, who is leading the study.
Authorities like the United States Centers for Disease Control and Prevention say people with compromised immune systems can receive the vaccine, but stress that there is still little data on safety.
“If you have a condition or are taking medications that weaken your immune system, you may NOT be fully protected even if you are fully vaccinated,” the CDC says, urging people to continue to take precautions and to consult their doctor.
People’s immune systems can be suppressed by disease or by treatments taken to deal with other conditions, and this may mean their body has trouble producing the antibodies vaccines are meant to trigger.
Conditions where this might be the case include diabetes, obesity, cancer, organ and bone marrow transplants, chronic severe kidney failure, HIV and multiple sclerosis.
In the case of a transplant, a patient’s immune response is suppressed on purpose to prevent his or her body from attacking the new organ.
Another French study published in the New England Journal of Medicine looked at 100 transplant patients and found their immune response to vaccines was insufficient after two doses.
Scientists recommended three doses for those patients, which has now become standard practice in France.
The new study, which involves 30 hospitals and has been signing up participants since March, is aiming to attract 8,650 participants with compromised immune systems and a control group of 1,850 uncompromised people.
Participants will have their blood drawn to measure the presence of antibodies at the time of vaccination and then again after one month, six months, one year and then two years after the last dose.
“The data will allow us to adapt our vaccine recommendations to specific patient populations,” Launay said.
Health authorities could, for example, decide to shorten the period between the first dose and the two or three booster shots that would likely follow for immune-compromised patients.
And in cases where vaccines failed to produce any results, doctors could opt for other strategies like vaccinating the patient’s family and caregivers, and maintaining social distancing.
If a vaccine failure results in infection with COVID-19, researchers will also sequence the virus. Doing so could pick up whether the illness is caused by an existing variant or identify new mutations.
While the novel coronavirus typically infects individuals for around 10 days before being neutralized by the body, some studies have shown that certain patients — particularly those with compromised immune systems — may carry it for several weeks or longer. That increases the window of opportunity for the virus to mutate, potentially resulting in new variants.
A similar study was launched in the U.K. in March, which will monitor 5,000 immunocompromised patients’ responses to COVID-19 vaccinations.
“We urgently need to understand if patient populations with chronic conditions such as cancer, inflammatory arthritis and kidney and liver disease are likely to be well-protected by current COVID-19 vaccines,” lead researcher Iain McInnes of the University of Glasgow said at the time.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.